Exploration of Targeted Anti-tumor Therapy

Table 5. Alterations of frequently mutated genes of colorectal cancer in colorectal cancer cell lines with or without APC and other WNT/β-catenin pathway mutations

Cell line	*TP53*	*KRAS*	*NRAS*	*BRAF*	*PIK3CA*	*APC*	*RNF43*	*CTNNB1*	*TCF7L2*
Quadruple mutated
CL-34	S127P, K382Nfs*40	WT	WT	*V600E	WT	T1556Nfs3, E418, R856C	WT	WT	K468Sfs23, L200I
CW-2	WT	P140H	WT	WT	P283S	S1465Wfs3, R302, G470R, A528V, E2737G, I2756V	WT	R582Q	C469Vfs8
GP2d	WT	*G12D	WT	T529A	*H1047L	T1445Lfs27, L2384I, S2562G, HD	S771T, D628G	D755V	W156
HCT-15	S241F, X367_splice	*G13D	WT	WT	E545K, D549N	I1417Lfs2, R2166, R727M, K993N, K1561N, E2550Q, I1779M	G659Vfs41, L214M	WT	WT
KM12	H179R, V73Wfs*50	WT	WT	A712T, A404Cfs*9	WT	N1818Kfs2, G471E	G659Vfs41	SETD5 fusion	WT
LoVo	WT	*G13D	WT	WT	WT	R1114, M1431Cfs42, R2816Q	WT	*R535Q	K468Sfs23
LS411N	Y126	WT	WT	*V600E	WT	T1556Nfs3, Q789	G659Vfs41	WT	WT
NCI-H630	R342	WT	WT	WT	WT	Q1367, V1173M	WT	WT	K468Sfs23
SNU-C2A	R273C, R273H, *R273Y	*G12D	HD	WT	D725G	K2051Efs9	R337, C275Wfs*143, R389C	HD	K468Sfs23
SNU-C4	*G245S	WT	HD	D22N	*E545G, V71I	F801Lfs19, T1556Lfs9, H325R	R225Afs194	WT	K468Sfs23
SNU-C5	R248W, V218L	WT	WT	*V600E	*H1047R	N1792Kfs7	G659Vfs41	WT	WT
APC only mutated
C75	*R249S	WT	WT	WT	WT	Q1204, S943Qfs12, L1488Ffs23	WT	WT	WT
C80	Q52	*A146V	WT	WT	WT	L629	WT	WT	WT
C84	R342	*G12A	WT	WT	WT	R1450, R283, *R640W	WT	WT	WT
CACO2	C135F, E204*	WT	WT	WT	WT	Q1367	WT	G245A	WT
COLO 201	WT	WT	WT	*V600E	WT	T1556Nfs3	WT	WT	WT
DiFi	*K132R	WT	WT	WT	WT	E1151, E443Afs16	WT	WT	WT
GEO	WT	*G12A	WT	WT	WT	E1536, C344Vfs110	WT	WT	WT
HCC2998	R213	*A146T	WT	WT	WT	R1450, L665, I2167S, S1864Y, N2720K, R168I	WT	WT	WT
MDST8	WT	WT	WT	V600E, V600K, *V600M	WT	T1556Nfs3	WT	WT	WT
SK-CO-1	WT	*G12V, AMPL	WT	AMPL	WT	F1089fs37	WT	WT	WT
SNU-175	WT	*A59T	WT	NA	NA	R232, N1455fs18, G1499, A199V	WT	WT	WT
SW1116	*A159D	*G12A	WT	NA	AMPL	Q264, Q1429Hfs41	WT	WT	WT
SW1417	C238Hfs21	WT	WT	*V600E, AMPL	NA	R1450	WT	WT	WT
Triple mutated
HCC-56	*R196P	*G12V	WT	WT	WT	WT	WT	WT	*X387_splice
HCT 116	WT	*G13D	WT	WT	*H1047R	WT	R117Afs41	*S45del	Fusion
LIM1215	WT	WT	WT	WT	WT	WT	WT	*T41A, Q177P	NA
LS1034	*G245S, HD	*A146T, AMPL	WT	WT	WT	WT	WT	WT	R39Gfs4
NCI-H508	*R273H	WT	WT	*G596R	*E545K, AMPL	WT	WT	WT	Fusion, HD
NCI-H716	*E224D	R97I	WT	WT	WT	WT	H472Qfs30	WT	WT
RKO	WT	WT	WT	*V600E	*H1047R	WT	G659Vfs41, H549N	WT	WT
SNU-407	S90Pfs33	*G12D	WT	R726C	*H1047R	WT	WT	*T41A	K468Sfs23, A549T, A419V
SNU-C2B	*R273Y	*G12D	WT	WT	D725G	WT	C275Wfs143	WT	K468Sfs23
Quadruple wild type
C10	WT	WT	WT	WT	WT	WT	WT	WT	WT
C99	WT	WT	WT	WT	WT	WT	WT	WT	WT
CAR1	*V272M	WT	WT	WT	WT	WT	WT	WT	WT
LS513	WT	*G12D	WT	E204L, E204V, E204*	WT	WT	WT	WT	WT

Return to article view

AMPL: amplified; HD: Homodeleted; WT: wild type; NA: not available; APC: adenomatous polyposis coli. * before a mutation denotes oncogenic. Data are from the Cancer Cell Line Encyclopedia (CCLE)

Declarations

Author contributions

IAV: Conceptualization, Investigation, Writing—original draft, Writing—review & editing.

Conflicts of interest

The author declares that there have no conflicts of interest.

Ethical approval

The study was an analysis of previously published data and was exempt from approval by an Ethics Committee.

Consent to participate

The study was an analysis of previously published data and informed consent was not required or obtained.

Consent to publication

Not applicable.

Availability of data and materials

The datasets analyzed for this study can be found in the Cancer Genome Atlas [http://www.cancer.gov/ccg/]; Cancer Cell Line Encyclopedia [http://www.sites.broadintitute.org/ccle/]; Genomics of Drug Sensitivity in Cancer (GDSC) project [http://www.cancerrxgene.org]; project Achilles, Drive, Marcotte DEMETER2 [http://www.depmap.org/portal/achilles]; DepMap, Public 24Q2+Score, and Chronos projects [http://www.depmap.org].

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. Erratum in: CA Cancer J Clin. 2024;74:203. [DOI] [PubMed]

Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020;159:335–49.e15. [DOI] [PubMed] [PMC]

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:329–59. [DOI] [PubMed]

André T, Shiu K, Kim TW, Jensen BV, Jensen LH, Punt C, et al.; KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383:2207–18. [DOI] [PubMed]

Kopetz S, Grothey A, Yaeger R, Cutsem EV, Desai J, Yoshino T, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019;381:1632–43. [DOI] [PubMed]

Siena S, Bartolomeo MD, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al.; DESTINY-CRC01 investigators. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22:779–89. [DOI] [PubMed]

Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;388:44–54. [DOI] [PubMed] [PMC]

Pathak PS, Chan G, Deming DA, Chee CE. State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation. Am Soc Clin Oncol Educ Book. 2024;44:e438466. [DOI] [PubMed]

Voutsadakis IA. KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics. Crit Rev Oncol Hematol. 2023;186:103987. [DOI] [PubMed]

10.

Fasano M, Pirozzi M, Miceli CC, Cocule M, Caraglia M, Boccellino M, et al. TGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities. Int J Mol Sci. 2024;25:7400. [DOI] [PubMed] [PMC]

11.

Fujita M, Demizu Y. Advances in the development of Wnt/β-catenin signaling inhibitors. [Epub ahead of print]. 2024 [cited 2024 Nov 02]. [DOI] [PubMed] [PMC]

12.

Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7. [DOI] [PubMed] [PMC]

13.

Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016;15:857–65. Erratum in: Cell Rep. 2016;17:1206. [DOI] [PubMed] [PMC]

14.

Voutsadakis IA. The ubiquitin-proteasome system in colorectal cancer. Biochim Biophys Acta. 2008;1782:800–8. [DOI] [PubMed]

15.

Hankey W, Frankel WL, Groden J. Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. Cancer Metastasis Rev. 2018;37:159–72. [DOI] [PubMed] [PMC]

16.

Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, et al.; MC3 Working Group; Cancer Genome Atlas Research Network. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018;6:271–81.e7. [DOI] [PubMed] [PMC]

17.

Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41. [DOI] [PubMed] [PMC]

18.

Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30:413–21. [DOI] [PubMed] [PMC]

19.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7. Erratum in: Nature. 2012;492:290. Erratum in: Nature. 2019;565:E5–6. [DOI] [PubMed] [PMC]

20.

Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. 2016;166:740–54. [DOI] [PubMed] [PMC]

21.

Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019;568:511–6. [DOI] [PubMed]

22.

Boehm JS, Garnett MJ, Adams DJ, Francies HE, Golub TR, Hahn WC, et al. Cancer research needs a better map. Nature. 2021;589:514–6. [DOI] [PubMed]

23.

van der Meer D, Barthorpe S, Yang W, Lightfoot H, Hall C, Gilbert J, et al. Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models. Nucleic Acids Res. 2019;47:D923–9. [DOI] [PubMed] [PMC]

24.

Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a Cancer Dependency Map. Cell. 2017;170:564–76.e16. [DOI] [PubMed] [PMC]

25.

Marcotte R, Sayad A, Brown KR, Sanchez-Garcia F, Reimand J, Haider M, et al. Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell. 2016;164:293–309. [DOI] [PubMed] [PMC]

26.

Dwane L, Behan FM, Gonçalves E, Lightfoot H, Yang W, van der Meer D, et al. Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets. Nucleic Acids Res. 2021;49:D1365–72. [DOI] [PubMed] [PMC]

27.

Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49:1779–84. [DOI] [PubMed] [PMC]

28.

Dempster JM, Boyle I, Vazquez F, Root DE, Boehm JS, Hahn WC, et al. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 2021;22:343. [DOI] [PubMed] [PMC]

29.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4. Erratum in: Cancer Discov. 2012;2:960. [DOI] [PubMed] [PMC]

30.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. [DOI] [PubMed] [PMC]

31.

Baulies A, Angelis N, Li VSW. Hallmarks of intestinal stem cells. Development. 2020;147:dev182675. [DOI] [PubMed]

32.

Basak O, Beumer J, Wiebrands K, Seno H, Oudenaarden Av, Clevers H. Induced Quiescence of Lgr5+ Stem Cells in Intestinal Organoids Enables Differentiation of Hormone-Producing Enteroendocrine Cells. Cell Stem Cell. 2017;20:177–90.e4. [DOI] [PubMed]

33.

Zhang C, Jin Y, Marchetti M, Lewis MR, Hammouda OT, Edgar BA. EGFR signaling activates intestinal stem cells by promoting mitochondrial biogenesis and β-oxidation. Curr Biol. 2022;32:3704–19.e7. [DOI] [PubMed] [PMC]

34.

Voutsadakis IA. Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med. 2007;11:252–85. [DOI] [PubMed] [PMC]

35.

Perochon J, Carroll LR, Cordero JB. Wnt Signalling in Intestinal Stem Cells: Lessons from Mice and Flies. Genes (Basel). 2018;9:138. [DOI] [PubMed] [PMC]

36.

Voutsadakis IA. Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer. J Clin Med. 2023;12:411. [DOI] [PubMed] [PMC]

37.

Tabernero J, Cutsem EV, Garralda E, Tai D, Braud FD, Geva R, et al. A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF^V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. Oncologist. 2023;28:230–8. [DOI] [PubMed] [PMC]

38.

Lung H, Wentworth KL, Moody T, Zamarioli A, Ram A, Ganesh G, et al. Wnt pathway inhibition with the porcupine inhibitor LGK974 decreases trabecular bone but not fibrosis in a murine model with fibrotic bone. JBMR Plus. 2024;8:ziae011. [DOI] [PubMed] [PMC]

39.

Kim MK. Novel insight into the function of tankyrase. Oncol Lett. 2018;16:6895–902. [DOI] [PubMed] [PMC]

40.

Klement K, Brückner M, Bernkopf DB. Phosphorylation of axin within biomolecular condensates counteracts its tankyrase-mediated degradation. J Cell Sci. 2023;136:jcs261214. [DOI] [PubMed] [PMC]

41.

Fearon ER. PARsing the phrase “all in for Axin” - Wnt pathway targets in cancer. Cancer Cell. 2009;16:366–8. [DOI] [PubMed]

42.

Huang SA, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461:614–20. [DOI] [PubMed]

43.

Masuda M, Sawa M, Yamada T. Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer. Pharmacol Ther. 2015;156:1–9. [DOI] [PubMed]

44.

Shitashige M, Satow R, Jigami T, Aoki K, Honda K, Shibata T, et al. Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Res. 2010;70:5024–33. [DOI] [PubMed]

45.

Yamamoto D, Oshima H, Wang D, Takeda H, Kita K, Lei X, et al. Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer. J Pathol. 2022;257:39–52. [DOI] [PubMed] [PMC]

46.

Stefanski CD, Prosperi JR. Wnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response. Int J Mol Sci. 2020;21:7844. [DOI] [PubMed] [PMC]

47.

Lessey LR, Robinson SC, Chaudhary R, Daniel JM. Adherens junction proteins on the move-From the membrane to the nucleus in intestinal diseases. Front Cell Dev Biol. 2022;10:998373. [DOI] [PubMed] [PMC]